Holen Sie sich die Stockscreener-App
0.591
1.48%
-0.0089
Handel nachbörslich:
.58
-0.011
-1.86%
Schlusskurs vom Vortag:
$0.5999
Offen:
$0.58
24-Stunden-Volumen:
28,607
Relative Volume:
0.80
Marktkapitalisierung:
$24.14M
Einnahmen:
$15.12M
Nettoeinkommen (Verlust:
$-52.48M
KGV:
-0.4573
EPS:
-1.2924
Netto-Cashflow:
$-36.52M
1W Leistung:
-1.34%
1M Leistung:
-3.46%
6M Leistung:
-6.04%
1J Leistung:
-53.68%
1-Tages-Spanne:
$0.5702
$0.63
1-Wochen-Bereich:
$0.5503
$0.63
52-Wochen-Spanne:
$0.512
$1.83
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Firmenname
Barinthus Biotherapeutics Plc Adr
Sektor
Branche
Telefon
44 (0) 1865 818808
Adresse
20400 CENTURY BLVD, GERMANTOWN
Compare BRNS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
0.591 | 23.79M | 15.12M | -52.48M | -36.52M | -1.2924 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-05-25 | Eingeleitet | Jefferies | Buy |
| 2021-05-25 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-25 | Eingeleitet | William Blair | Outperform |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Aktie (BRNS) Neueste Nachrichten
Barinthus Biotherapeutics (Nasdaq: BRNS) details Q2 loss, cash and Clywedog merger plan - Stock Titan
Barinthus Biotherapeutics plc Sponsored ADR Revenue Breakdown – GETTEX:2AB - TradingView
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy - Yahoo Finance
What Makes Protara Therapeutics (TARA) a New Buy Stock - Yahoo Finance
Price to sales forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB - TradingView
Enterprise value to revenue forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB - TradingView
Price to earnings forward of Barinthus Biotherapeutics plc Sponsored ADR – DUS:2AB - TradingView
2AB Forecast — Price Target — Prediction for 2027 - TradingView
Burke & Herbert (BHRB) Upgraded to Buy: Here's Why - Yahoo Finance
All You Need to Know About Sera Prognostics (SERA) Rating Upgrade to Buy - Yahoo Finance
Bayer (BAYRY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BeOne Medicines Ltd.Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Bain Capital Specialty (BCSF) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BRNSBarinthus Biotherapeutics Plc ADR Stock Price and Quote - Finviz
Barinthus Biotherapeutics shareholders approve scheme of arrangement - Investing.com
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
What Makes Biorestorative Therapies (BRTX) a New Buy Stock - Yahoo Finance
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders? - Morningstar
USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Why Qualcomm Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Sahm
Barinthus Biotherapeutics (NASDAQ: BRNS) cuts Q1 loss while pursuing Clywedog merger - Stock Titan
What Makes Haleon PLC Sponsored ADR (HLN) a New Buy Stock - Yahoo Finance
Why Brainsway (BWAY) Might be Well Poised for a Surge - Yahoo Finance
ProShares Russell 2000 Dividend Growers ETF $SMDV Shares Sold by Capital Investment Advisors LLC - Defense World
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy - Yahoo Finance
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why - Yahoo Finance
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? - Finviz
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why - Yahoo Finance
Haleon PLC Sponsored ADR (HLN) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Banco Santander-Brazil (BSBR) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
BioHarvest Sciences Inc. (NASDAQ:BHST) Sees Large Increase in Short Interest - Defense World
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Should I buy Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) - Zacks Investment Research
Barinthus Bio reports positive initial data from celiac therapy trial - Investing.com
Barinthus Bio joins forces with metabolic disease biotech in reverse merger - Fierce Biotech
Liminatus Pharma (LIMN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Surging Earnings Estimates Signal Upside for Brainsway (BWAY) Stock - Yahoo Finance
Europe Shingles Vaccine Market Size & Outlook, 2025-2030 - Grand View Research
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Improved Revenues Required Before Barinthus Biotherapeutics plc (NASDAQ:BRNS) Stock's 29% Jump Looks Justified - Sahm
BRNS: Q1 2025 saw a $19.6M net loss and a strategic pivot to immunology, with cash runway into 2027 - TradingView
BRNS: Antigen-specific immunotherapies advance with strong clinical progress and robust financials - TradingView
Barinthus Biotherapeutics plc (ADR) (BRNS) Live Share Price, Invest From India - INDmoney
BRNS: 2024 net loss narrowed to $61.2M; major restructuring extends cash runway into 2027 - TradingView
Finanzdaten der Barinthus Biotherapeutics Plc Adr-Aktie (BRNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):